Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.

Item

http://www.wikidata.org/entity/Q42276735

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Lipid-lowering effect and effi ...... olerance to suppressive HAART.

@en

Lipid-lowering effect and effi ...... olerance to suppressive HAART.

@nl

type

Item

label

Lipid-lowering effect and effi ...... olerance to suppressive HAART.

@en

Lipid-lowering effect and effi ...... olerance to suppressive HAART.

@nl

prefLabel

Lipid-lowering effect and effi ...... olerance to suppressive HAART.

@en

Lipid-lowering effect and effi ...... olerance to suppressive HAART.

@nl

P1476

Lipid-lowering effect and effi ...... olerance to suppressive HAART.

@en

P2093

Ignacio de Los Santos

http://www.w3.org/2001/XMLSchema#string

Jesús Sanz

http://www.w3.org/2001/XMLSchema#string

José L Casado

http://www.w3.org/2001/XMLSchema#string

Lucio García-Fraile

http://www.w3.org/2001/XMLSchema#string

María Del Palacio

http://www.w3.org/2001/XMLSchema#string

María J Pérez-Elías

http://www.w3.org/2001/XMLSchema#string

Santiago Moreno

http://www.w3.org/2001/XMLSchema#string

P2860

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.

State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary

Class-sparing regimens for initial treatment of HIV-1 infection.

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HCT1401-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23372109

http://www.w3.org/2001/XMLSchema#string